ArticleGeburtshilfe und Frauenheilkunde2026
High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer - Results from a Large Real-World Claims Data Analysis in Germany.
Article in Geburtshilfe und Frauenheilkunde, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis.Archives of gynecology and obstetrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In hormone-receptor positive (HR+) early breast cancer (EBC), adjuvant endocrine therapy (ET) significantly reduces recurrence and mortality. A common means of estimating therapy adherence is to use patient-reported outcome measures. Yet, this method is inaccurate due to social-desirability bias. We therefore aimed to analyze adherence to ET over the first five years of treatment by using claims data from a large health insurance provider in Germany (AOK Baden-Wuerttemberg). Female patients diagnosed with HR+ EBC who received inpatient treatment and breast cancer surgery between 1 July 2010 and 31 December 2019 were included in the analysis. Adherence to ET was defined as the ratio between the sum of the number of pills from filled prescriptions and the duration of ET in days (from the start of the first prescription after completing surgery and chemotherapy). ET use was observed over five years. Low adherence was defined as a ratio smaller than 0.8 and high adherence as a ratio larger than or equal to 0.8. Distant recurrence-free survival (DRFS) was calculated from the day of the first diagnosis of EBC until onset of distant recurrence. Overall survival (OS) was defined as the period between first diagnosis of EBC until death of any cause. In total, 16642 patients with EBC were included. Of these patients, 4303 (86%) showed high adherence to ET in the first year after initiating treatment. After five years, high adherence persisted in 68% of patients. Continuous high adherence to ET had a significant impact on DRFS (HR: 0.66; 95% CI: 0.58-0.76, p > 0.0001) and OS (HR 0.52, 95% CI: 0.47-0.57, p < 0.0001). In conclusion, adherence to ET is an independent risk factor that significantly influences DRFS and OS. Further real-world studies should explore the factors contributing to treatment discontinuation and evaluate prospective strategies to enhance adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.